Treatment of corneal neovascularization

Abstract

There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.

1 . A method of preventing corneal neovascularization (“CNV”) which comprises administering to a subject in need thereof a therapeutically effective amount of an NK-1 antagonist selected from the group consisting of fosaprepitant, aprepitant, lanepitant and befetupitant and pharmaceutically acceptable salts of any one thereof, wherein the NK-1 antagonist is administered topically to the cornea. 
     
     
         2 . The method of  claim 1  wherein CNV is concurrent or consequential to an inflammatory condition. 
     
     
         3 . The method of  claim 1  wherein CNV is caused by one of the following conditions: bacterial infection, viral infection,  Chlamydia trachomatis  infection, infectious keratitis including herpes simplex keratitis, viral interstitial keratitis, infections caused by  staphylococcus, streptococcus, Pseudomonas  or microbial keratoconjunctivitis,  Pseudomonas aeruginosa  infection, chemical or physical insult of the eye, degenerative and traumatic disorders, dry eye, progressive corneal vascularization caused by graft-versus-host disease, limbal stem cell deficiency (including idiopathic, traumatic, aniridia, autoimmune polyendocrinopathy), Stevens-Johnson syndrome, ocular pemphigoid, recurrent pterygium following surgery, extended wearing of hydrogel contact lenses. 
     
     
         4 . The method of  claim 1  wherein the NK-1 antagonist is aprepitant or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The method of  claim 1  wherein the NK-1 antagonist is befetupitant or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method of  claim 1  wherein the NK-1 antagonist is lanepitant or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The method of  claim 1  wherein the NK-1 antagonist is fosaprepitant or a pharmaceutically acceptable salt thereof. 
     
     
         8 . The method of  claim 1  wherein the NK-1 antagonist is administered in combination, by the same or a different route, with one or more further therapeutically active agents. 
     
     
         9 . The method of  claim 8  wherein the at least one of the one or more further therapeutically active agents is administered topically to the eye.